Kiniksa Pharmaceuticals (KNSA) COO reports option exercise and share sale

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc reported an insider transaction by its Chief Operating Officer on 12/15/2025. The COO exercised an employee share option to acquire 6,000 Class A Ordinary Shares at an exercise price of $8.83 per share, then sold 12,048 Class A Ordinary Shares at a weighted average price of $41.56 per share through multiple trades.

After these transactions, the reporting person beneficially owned 16,666 Class A Ordinary Shares, held directly. The filing states that the trades were made under a pre-established Rule 10b5-1 trading plan executed on April 29, 2024, and notes that the option involved in this transaction was fully vested and exercisable.

Insider Trade Summary

Net Seller: 12,048 shares ($500,715)

Net Sell 3 txns

Insider Tessari Eben

Role CHIEF OPERATING OFFICER

Sold 12,048 shs ($501K)

Type	Security	Shares	Price	Value
Exercise	Share Option	6,000	$0.00	--
Exercise	Class A Ordinary Share	6,000	$8.83	$53K
Sale	Class A Ordinary Share	12,048	$41.56	$501K

Holdings After Transaction: Share Option — 0 shares (Direct); Class A Ordinary Share — 28,714 shares (Direct)

Footnotes (1)

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $41.235 and $41.78. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. The option is fully vested and exercisable.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tessari Eben

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INTERNATIONA

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON X0 W1J 7NJ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF OPERATING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	12/15/2025		M(1)		6,000	A	$8.83	28,714	D
Class A Ordinary Share	12/15/2025		S(1)		12,048	D	$41.56(2)	16,666	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$8.83	12/15/2025		M(1)			6,000	(3)	09/16/2029	Class A Ordinary Share	6,000	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $41.235 and $41.78. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

3. The option is fully vested and exercisable.

	/s/ Douglas Barry, Attorney-in-Fact	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Kiniksa Pharmaceuticals (KNSA) report for its COO?

The Chief Operating Officer exercised an option to acquire 6,000 Class A Ordinary Shares at $8.83 per share on 12/15/2025, and sold 12,048 Class A Ordinary Shares the same day.

At what price were the KNSA shares sold in the reported Form 4 transaction?

The 12,048 Class A Ordinary Shares were sold at a weighted average price of $41.56 per share, based on multiple trades executed between $41.235 and $41.78.

How many Kiniksa Pharmaceuticals (KNSA) shares does the reporting person own after this transaction?

Following the reported transactions, the reporting person beneficially owns 16,666 Class A Ordinary Shares, held directly.

Was the KNSA insider trade made under a Rule 10b5-1 trading plan?

Yes. The filing states that the transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on April 29, 2024.

What happened to the share option reported in the KNSA Form 4?

The reported share option had an exercise price of $8.83 and covered 6,000 Class A Ordinary Shares. It was fully vested and exercisable, and after the exercise on 12/15/2025, 0 derivative securities of that option remained beneficially owned.

What is the role of the reporting person in Kiniksa Pharmaceuticals (KNSA)?

The reporting person is an officer of Kiniksa Pharmaceuticals International, plc, serving as its Chief Operating Officer.